Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
Therapies traditionally targeting neurohormonal pathways were most consistently associated with preservation of LVEF, whereas statins and ARNIs showed greater benefit when broader, study-defined cardiotoxicity criteria were applied, whereas ACE inhibitors did not demonstrate consistent benefit.
Abstract
Cancer therapy-related cardiac dysfunction (CTRCD) is an important complication of cancer treatment that may lead to interruption of treatment. Anthracyclines and anti-HER2 therapies are highly effective but carry risk of myocardial injury, ranging from subclinical changes to overt heart failure. Clinical trials data evaluating cardioprotective strategies remain heterogeneous and lacking direct comparisons between drug classes. Consequently, the optimal pharmacologic approach to cardioprotection remains uncertain. We performed a systematic review and network meta-analysis (NMA) of randomised trials evaluating pharmacologic strategies for primary prevention of CTRCD.
MEDLINE and Embase were searched from inception to Feb 2026. We included randomised controlled trials enrolling adults receiving anthracycline- and/or anti-HER2–based chemotherapy that evaluated primary prevention of CTRCD. Interventions included beta-blockers, ACE inhibitors, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRA), statins, angiotensin receptor–neprilysin inhibitors (ARNI), and combination regimens. The primary outcome was incidence of clinically meaningful CTRCD (LVEF <50%). Secondary outcomes were study-defined cardiotoxicity (which have changed in definition over time) and absolute change in LVEF. Where LVEF <50% was not reported, proportions were derived assuming normal distribution of follow-up LVEF values.
Forty-two trials (94 treatment arms) were included. For incident LVEF <50%, MRAs demonstrated the largest effect (OR 0.06, 95% CI 0.01–0.44), followed by dual therapy [beta blocker + ACEi/ARB] (OR 0.26, 0.10–0.66) and ACE inhibitors (OR 0.29, 0.10–0.85). Beta-blockers (OR 0.55, 0.33–0.91) and statins (OR 0.52, 0.29–0.94) were also associated with reduced risk, while ARBs and ARNIs were not significant.Secondary analyses suggested divergence across endpoints. Using contemporary, study-defined cardiotoxicity criteria, statins and ARNIs performed best, whereas ACE inhibitors did not demonstrate consistent benefit. ARBs showed no signal of efficacy across outcomes.
Cardioprotective therapy was associated with reduced CTRCD, with effects varying by drug class and outcome definition. Therapies traditionally targeting neurohormonal pathways were most consistently associated with preservation of LVEF, whereas statins and ARNIs showed greater benefit when broader, study-defined cardiotoxicity criteria were applied. In contrast, ARBs demonstrated no consistent signal of efficacy across analyses. Treatment benefit is sensitive to outcome definition, which may partly explain heterogeneity across trials. These findings may have important clinical implications for the choice of cardioprotective therapies in cancer patients undergoing anthracycline or anti-HER2 based therapy.Table 1Figure 1
Anthracycline-induced cardiac dysfunction (AICD) is cardiac injury associated with potentially cardiotoxic anthracycline therapy, and remains a significant complication for breast cancer patients. Neurohormonal modulation, a therapeutic strategy used primarily in heart failure, including renin–angiotensin system...
R. B. Sidabukke, N. P. Simangunsong, L. A. A. Hadid· European Heart Journal, Supp...· 0 citations
Background Trastuzumab has substantially improved clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, but treatment-related cardiac dysfunction may compromise treatment continuity and long-term cardiovascular health. This systematic review and meta-analysis evaluat...
Yu-Kun Liu, Lin-Lin Zhang, Jie Guan et al.· Translational Cancer Researc...· 0 citations
Purpose Anthracycline-induced cardiotoxicity remains an important complication in patients with breast cancer receiving systemic therapy, and effective preventive strategies remain limited. We conducted a systematic review and meta-analysis to evaluate the cardioprotective effects of beta-blockers in anthracycline-trea...
Victor M. Samperio, L. M. Murrieta Bruciaga, Jesús Antonio Castañeda Martínez et al.· Frontiers in Cardiovascular...· 0 citations
Anthracyclines are among the chemotherapeutic agents most strongly associated with cancer therapy–related cardiac dysfunction (CTRCD) and represent the class with the highest incidence of cardiotoxicity, affecting up to one third of exposed patients. Anthracycline-induced cardiotoxicity frequently manifests as He...
L. García Mena, E. Pinzón Cueva, A. García-Rueda et al.· European Heart Journal· 0 citations
As cancer survival continues to improve, cancer therapy-related cardiovascular toxicity, including cancer therapeutics-related cardiac dysfunction (CTRCD) and heart failure (HF), has emerged as a major clinical challenge. Growing evidence supports a bidirectional relationship between cancer and HF, driven by shared ris...
H. Park, Nuri Lee, Seong-Mi Park· International Journal of Hea...· 0 citations
Chemotherapy-related cardiac dysfunction (CTRCD) is a major limitation of cardiotoxic cancer therapies. Although global longitudinal strain (GLS) allows early detection of myocardial injury, preventive strategies remain scarce. Angiotensin receptor–neprilysin inhibitors (ARNIs) may offer cardioprotection, but cur...
R. Huntermann, M. Molinari, P. Batista et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.